Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...